Cancer gene therapy using a replication- competent herpes simplex virus type 1 vector

Annals of Surgery

Volumn 228, Issue 3, 1998, Pages 366-374

  Yoon, Sam S ^a   Carroll, Nancy M ^a   Chiocca, E Antonio ^a   Tanabe, Kenneth K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBONUCLEOTIDE REDUCTASE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER THERAPY; COLON CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; GENE THERAPY; HERPES SIMPLEX VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; ANTIMETABOLITES; CARCINOMA; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; GANCICLOVIR; GENE THERAPY; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MICE, NUDE; TUMOR CELLS, CULTURED;

EID: 0032471162     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199809000-00009     Document Type: Conference Paper

References (23)

1. Hussein AM. The potential applications of gene transfer in the treatment of patients with cancer: a concise review. Cancer Invest 1996; 14:343-352.
2. Panis Y, Rad ARK, Boyer O, et al. Gene therapy for liver tumors. Surg Oncol Clin N Am 1996; 5:461-473.
3. Weichselbaum RR, Kufe D. Gene therapy of cancer. Lancet 1997; 349:SII10-12.
4. Marcel T, Grausz JD. The TMC worldwide gene therapy enrollment report, end 1996. Hum Gene Ther 1997; 8:775-800.
5. Breakefield XO, Kramm CM, Chiocca EA, Pechan PA. Herpes simplex virus vectors for tumor therapy. In: Sobel RE. Scanlon KJ. ed. The Internet Book of Gene Therapy. Cancer Therapeutics. Hartford: Appleton & Lange: 1995; 41-56.
6. Crumpacker CS. Ganciclovir. N Engl J Med 1996; 335:721-727.
7. Carroll NM, Chase M, Chiocca EA, Tanabe KK. The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J Surg Res 1997; 69:413-417.
8. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62:196-205.
9. Fong Y, Blumgart LH, Cohen AM. Surgical treatment of colorectal metastases to the liver. CA Cancer J Clin 1995; 45:50-62.
10. Millikan KW, Staren ED, Doolas A. Invasive therapy of metastatic colorectal cancer to the liver. Surg Clin North Am 1997; 77:27-48.
11. Carroll NM, Chiocca EA, Takahashi K, Tanabe KK. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 1996; 224:323-329.
12. Kramm CM, Chase M, Herrliner U. et al. Therapeutic efficiency and safety of second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997; 8:2057-2068.
13. Li AP, Roque MA, Beck DJ, Kaminski DL. Isolation and culturing of hepatocytes from human livers. J Tiss Cult Meth 1992; 14:139-146.
14. Chen S, Li Chen XH, Wang Y, et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci 1995; 92:2577-2581.
15. Caruso M, Pham-Nguyen K, Kwong Y, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci 1996; 93:11302-11306.
16. Hurford RK, Dranoff G, Mulligan RC, Tepper RI. Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat Genet 1995; 10:430-435.
17. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53:5274-5283.
18. Trinh QT, Austin EA, Murray DM, et al. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 1995; 55:4808-4812.
19. Paillard F. Bystander effects in enzyme/prodrug gene therapy. Hum Gene Ther 1997; 8:1733-1736.
20. Huber BE, Austin EA, Good SS, et al. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993; 53:4619-4626.
21. Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide gene therapy. Lancet 1997; 349:2-3.
22. Kong H, Crystal RG. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 1998; 90:273-286.
23. Couffinhal T, Kearney M, Sullivan A, et al. Histochemical staining following lacZ gene transfer underestimates transfection efficiency. Hum Gene Ther 1997; 8:929-934.